EcoDrugPlus

Neuropeptide Y Receptor Y2

Ensembl ID : ENSMMDG00005000149
Gene Symbol: NPY2R
1 Cross references
184 Possible Orthologues:

Neuropeptide Y Receptor Type 2-Like

Ensembl ID : ENSMMDG00005015990
Gene Symbol: LOC115376559
3 Cross references
178 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSMMDG00005018578
Gene Symbol: NTSR1
3 Cross references
202 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSMMDG00005024674
Gene Symbol: NTRK2
1 Cross references
207 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSMMDG00005000233
Gene Symbol: NTRK3
1 Cross references
203 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSMMDG00005003805
Gene Symbol: NTRK3
1 Cross references
193 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 1

Ensembl ID : ENSMMDG00005003192
Gene Symbol: NTRK1
1 Cross references
199 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSMMDG00005016506
Gene Symbol: NTRK2B
1 Cross references
210 Possible Orthologues:

Nicastrin

Ensembl ID : ENSMMDG00005012188
Gene Symbol: NCSTN
3 Cross references
203 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSMMDG00005007254
Gene Symbol: NAMPT
3 Cross references
225 Possible Orthologues:

Nischarin

Ensembl ID : ENSMMDG00005009741
Gene Symbol: NISCH
1 Cross references
208 Possible Orthologues:

Notch Receptor 1b

Ensembl ID : ENSMMDG00005013617
Gene Symbol: NOTCH1B
1 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).